Cautious Amid Middle East Escalation

The S&P/ASX 200 finished the week down 0.5%. The pullback came after fresh US strikes on Iran, and the return of US oil sanctions left the countries' truce in limbo, raising uncertainty over energy flows through the Strait of Hormuz and reigniting inflation and rate concerns. Despite that, the market is holding a cautious approach, rather than completely selling off, treating the latest escalation as another step in a managed conflict. 

This week’s best performers

Mesoblast (ASX:MSB) +8.74%

Mesoblast develops cell therapies, including Ryoncil, the only FDA-approved treatment for a serious transplant complication in children. Shares jumped after fourth-quarter revenue hit $36 million, beating expectations and lifting full-year revenue to $115 million as uptake accelerates across major US paediatric transplant centres. The stock is still down 19% year-to-date, but the revenue is proof the commercial rollout is gaining real traction. Ryoncil also carries orphan drug status, which blocks the FDA from approving a competing version of the same treatment until 2032, giving Mesoblast a clear run to keep building sales.

Santos (ASX:STO) +7.32%

Santos, one of Australia's largest oil and gas producers had a strong week, as oil prices jumped roughly 3% on rising US-Iran tensions, lifting the whole energy sector. But there's also a company-specific story. Barossa is nearing full output and Pikka in Alaska is ramping toward continuous production, setting up a genuine free cash flow boost on top of the oil price bump. Management wants to return 60% of that cash to shareholders and cut $2.5 billion of debt by 2030, though the rally could stall fast if oil prices or project timelines slip. 

Vault Minerals (ASX:VAU) +6.80%

The mid-tier Australian gold producer benefitted from a binding $5.6 billion takeover bid from Genesis Minerals which topped the merger Vault had already agreed to with Regis Resources in May. Genesis offered cash plus scrip, a 15.7% premium to Vault's last close, versus Regis's all-share deal. The Vault Minerals board has called it superior. Regis now has five business days to counter, so the next move is on them, whether they walk away or spark a full bidding war. 

This week's worst performers

Minerals 260 (ASX:MI6) -18.42%

The company behind the Bullabulling Gold Project in Western Australia had a disappointing week despite its prefeasibility study showing strong numbers, including a $2.3 billion NPV and 6.2-million-ounce resource, but the market focused on the size of the upfront build cost instead. Broker Morgans called the sell-off overdone, keeping a price target of $1.38, more than double the current price.

Electro Optic Systems (ASX:EOS) -17.14%

The remote weapon systems and space technology manufacturer had a down week without a single clear catalyst for the big drop. EOS shares are still up around 150% over the past year, even after falling almost 12% in the past month. The company has kept landing work, including a US$124 million counter-drone deal with a UAE defence firm.

Elevra Lithium (ASX:ELV) -16.10%

The lithium producer’s shares fell despite a strong June quarter, with production up 15% to 54,479 tonnes of spodumene concentrate, the mine's second-best on record. The catch is pricing: Elevra's realised lithium price is lagging the spot market, so stronger output isn't yet showing up in revenue.